N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction

Canadian Journal of Cardiology

Volumn 22, Issue 5, 2006, Pages 393-397

  Ezekowitz, Justin A ^a   Théroux, Pierre ^b   Chang, Weiching ^a   Mahaffey, Kenneth W ^c   Granger, Christopher B ^c   Weaver, W D ^d   Hochman, Judith S ^e   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Clinical trial; Myocardial infarction; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; N TERMINAL BRAIN NATRIURETIC PROPEPTIDE; PEXELIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANGIOPLASTY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE COURSE; DISEASE DURATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; QRS COMPLEX; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; STATISTICAL MODEL; STROKE; SYMPTOM;

EID: 33744785089     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70924-2     Document Type: Article

References (25)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
2. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
3. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
4. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108-275-81.
5. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
6. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-21.
7. Inoue T, Sakuma M, Yaguchi I, et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 2002;143-790-6.
8. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
9. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108-1184-90.
10. Hindman NB, Schocken DD, Widmann M, et al. Evaluation of a QRS scoring system for estimating infarct size. V. Specificity and method of application of the complete system. Am J Cardiol 1985;55:1485-90.
11. Schroder R, Wegscheider K, Schroder K, Dissmann R, Meyer-Sabellek W. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995;26:1657-64.
12. Passamani E. The Thrombolysis In Myocardial Infarction (TIMI) trial. N Engl J Med 1985;312:932-6.
13. Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996;27:1656-61.
14. Crilley JG, Farrer M. Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 2001;86:638-42.
15. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004;44:335-9.
16. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
17. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97-1921-9.
18. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
19. Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho O, Leppaluoto J, Huikuri HV. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004;43:757-63.
20. Berger R, Huelsman M, Strecker K, et al. B-Type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
21. Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.
22. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001;7:21-9.
23. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
24. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9.
25. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.